VERA at a glance
Vera Therapeutics, Inc. (VERA, SEC CIK 1831828) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 15, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Vera Therapeutics, Inc. (VERA) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Fordyce Marshall on September 15, 2026 of 18,500 shares at $37.00 per share.
- In the last 90 days, VERA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.3M
- 13F holders
- 30 funds
- $1.2B · +0 vs prior quarter
- Latest 8-K
- Sep 15, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
- Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments
- Key operational risk from reliance on specialized cybersecurity personnel with 29 and 28 years’ experience in biotech IT and security
- Incident response plan escalates incidents to management and board audit committee, ensuring rapid mitigation and remediation
- Regular management updates and external briefings to monitor and mitigate evolving cybersecurity threats
AI summary of the VERA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly added commercialization risk triggered by TRUTAKNA’s July 7, 2026 FDA accelerated approval and first expected product revenue in Q3 2026
- Most materially updated operating risk: transition from clinical development to commercial operations, with no prior successful product commercialization experience
- Regulatory risk: accelerated approval for IgAN may require additional FDA post-approval evidence, potentially limiting continued marketing
- Near-term market risk: TRUTAKNA adoption depends on physician and patient acceptance, reimbursement, pricing, and competing therapies
- Financial risk: $499.2 million in cash, equivalents, and marketable securities versus $75.0 million outstanding debt as of June 30, 2026
AI summary of the VERA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- TRUTAKNA preserved kidney function: eGFR change +2 vs -5.7 mL/min/1.73m² at 52 weeks
- Annualized eGFR decline improved to -0.6 vs -5.6 mL/min/1.73m²/year through 104 weeks
Item EX-99.1: Item EX-99.1
- ORIGIN 3 met all prespecified endpoints in 428 patients, supporting TRUTAKNA’s potential transition from accelerated to full approval
- eGFR decline through 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/year, a 5.0 treatment effect with p<0.0001
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released August 10, 2026
- Corporate updates included alongside earnings release
Item EX-99.1: Item EX-99.1
- FDA accelerated approval and U.S. launch make TRUTAKNA Vera’s first commercial product and establish a potential IgAN growth platform
- ORIGIN 3 final efficacy analysis expected Q3 2026, with supplemental BLA submission expected Q4 2026 and potential full approval in 2027
Item 5.02: Departure/Appointment of Directors or Principal Officers
- William Turner transitions from Chief Regulatory Officer to Special Advisor for Regulatory Affairs effective August 3, 2026
- Nancy Bowman, M.D., Ph.D. succeeds Turner as Chief Regulatory Officer on August 3, 2026
AI summaries of VERA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VERA
Don't miss the next VERA filing
- Alerts as it files. A push when VERA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VERA, by share count.
- Ask anything. An AI agent that reads every VERA filing and answers with sources.
VERA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fordyce Marshall | Sell | Sep 15, 2026 | 18,500 | $37.00 |
| Fordyce Marshall | M | Sep 15, 2026 | 18,500 | - |
| Fordyce Marshall | M | Sep 15, 2026 | 18,500 | $2.90 |
| Young Joseph R | M | Sep 11, 2026 | 5,000 | $3.94 |
| Young Joseph R | M | Sep 11, 2026 | 5,000 | - |
| Fordyce Marshall | M | Sep 2, 2026 | 18,500 | $2.90 |
| Fordyce Marshall | M | Sep 2, 2026 | 18,500 | - |
| Fordyce Marshall | Sell | Sep 2, 2026 | 18,500 | $35.12 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$102.0M | -$167.2M | -$315.5M |
| Net Income | -$96.0M | -$152.1M | -$299.6M |
| Balance Sheet | |||
| Total Assets | $175.5M | $655.7M | $734.7M |
| Equity | - | $577.2M | $604.5M |
| ROE | - | -26.4% | -49.6% |
| Per Share | |||
| EPS | $-2.25 | $-2.75 | $-4.66 |
| Cash Flow | |||
| Operating CF | -$92.2M | -$134.7M | -$241.1M |
| CapEx | $63K | $972K | $630K |
Source: XBRL data in Vera Therapeutics, Inc. (VERA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VERA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $1.20B |
| Q1 2026 | 30 | $977.2M |
| Q4 2025 | 25 | $1.27B |
| Q3 2025 | 24 | $634.0M |
| Q2 2025 | 25 | $528.0M |
| Q1 2025 | 21 | $264.5M |
| Q4 2024 | 19 | $399.9M |
| Q3 2024 | 16 | $142.6M |
- Morgan Stanley+2.43M (+659%)
- State Street Corp+785.1K (+23%)
- BlackRock+659.7K (+13%)
- Dimensional Fund Advisors+249.1K (+89%)
- Goldman Sachs Group+246.9K (+22%)
- T. Rowe Price Group−561.1K (-12%)
- Renaissance Technologies LLC−177.8K (-39%)
- Two Sigma Investments−106.0K (-50%)
- Millennium Management−14.8K (-5%)
- JPMorgan Chase & Co−12.3K (-20%)
- Allstate+6.3K
- Principal Financial Group+4.9K
- Citadel Advisors LLC−429.8K
- Franklin Resources−7.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 190 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VERA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 8-K | May 26, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VERA SEC filings: frequently asked questions
Are VERA insiders buying or selling?
In the last 90 days, Vera Therapeutics, Inc. (VERA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.3 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VERA stock?
As of June 30, 2026, the largest Vera Therapeutics, Inc. (VERA) holders among the 13F filers tracked by SignalX were BlackRock ($246.6 million), State Street Corp ($178.0 million), T. Rowe Price Group ($172.2 million), Morgan Stanley ($120.1 million), FMR LLC (Fidelity) ($119.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in VERA's latest 10-K?
In the 10-K filed February 26, 2026, Vera Therapeutics, Inc. (VERA) flagged: Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm. Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments. (AI summary of the Risk Factors section.)
What did VERA report in its latest 8-K?
Vera Therapeutics, Inc. (VERA) filed an 8-K on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). TRUTAKNA preserved kidney function: eGFR change +2 vs -5.7 mL/min/1.73m² at 52 weeks.
What are the latest VERA SEC filings?
Vera Therapeutics, Inc. (VERA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 15, 2026 and a Form 4 insider filing on September 17, 2026.
What is VERA's SEC CIK number?
Vera Therapeutics, Inc. (VERA)'s SEC Central Index Key (CIK) is 1831828. EDGAR lists every VERA filing under that number.
Ask anything about VERA
The research agent reads VERA's filings, financials, insider trades and 13F holders, then answers with sources.